Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

<p>Table ST8: Data output of the CCLE cell line screening provided by Prof. Schreiber at Broad Institute.</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Ossia M. Eichhoff (14964145) (author)
Daljnji autori:	Corinne I. Stoffel (14964148) (author), Jan Käsler (14964151) (author), Luzia Briker (14964154) (author), Patrick Turko (14964157) (author), Gergely Karsai (14964160) (author), Nina Zila (14964163) (author), Verena Paulitschke (14964166) (author), Phil F. Cheng (14940278) (author), Alexander Leitner (14964169) (author), Andrea Bileck (14964172) (author), Nicola Zamboni (14964175) (author), Anja Irmisch (14964178) (author), Zsolt Balazs (14964181) (author), Aizhan Tastanova (14964184) (author), Susana Pascoal (14964187) (author), Pål Johansen (14964190) (author), Rebekka Wegmann (6698010) (author), Julien Mena (14964193) (author), Alaa Othman (14964196) (author), Vasanthi S. Viswanathan (14964199) (author), Judith Wenzina (14964202) (author), Andrea Aloia (14964205) (author), Annalisa Saltari (14964208) (author), Andreas Dzung (14964211) (author), Michael Krauthammer (14964214) (author), Stuart L. Schreiber (14964217) (author), Thorsten Hornemann (14964220) (author), Martin Distel (14964223) (author), Berend Snijder (14964226) (author), Reinhard Dummer (14850772) (author), Mitchell P. Levesque (14964229) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Resistance Reversal of drug resistance Metabolism Metabolomics Skin Cancers Melanoma Tumor Heterogeneity
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
od: Nicole A. Traphagen (16677391)
Izdano: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
od: Nicole A. Traphagen (16677391)
Izdano: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
od: Phyllis S.Y. Chong (17141520)
Izdano: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
od: Phyllis S.Y. Chong (17141520)
Izdano: (2025)

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Izdano: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
od: Kavya Ramkumar (16474203)
Izdano: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
od: Jennifer L. Cotton (17315204)
Izdano: (2025)

Table S8 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer
od: Nina Müller (16721126)
Izdano: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
od: Seung Yeon Oh (15051017)
Izdano: (2025)

Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Izdano: (2025)

Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Izdano: (2025)

Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_74letsncsnlrf8olvlm1h6u3bg